phenylalanylphenylalanylamide and Alloxan Diabetes

phenylalanylphenylalanylamide has been researched along with Alloxan Diabetes in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Asato, M; Carlsson, A; Fransson, R; Hallberg, M; Kamei, J; Koizumi, T; Nakanishi, Y; Nyberg, F; Ohsawa, M; Sandström, A	1

Other Studies

1 other study(ies) available for phenylalanylphenylalanylamide and Alloxan Diabetes

Article	Year
The dipeptide Phe-Phe amide attenuates signs of hyperalgesia, allodynia and nociception in diabetic mice using a mechanism involving the sigma receptor system. Molecular pain, 2011, Oct-31, Volume: 7 Topics: Animals; Blotting, Western; Diabetes Mellitus, Experimental; Dipeptides; Hyperalgesia; Male; MAP Kinase Signaling System; Mice; Mice, Inbred ICR; Nociception; Pentazocine; Phosphorylation; Receptors, sigma; Reverse Transcriptase Polymerase Chain Reaction	2011

Article

Year

The dipeptide Phe-Phe amide attenuates signs of hyperalgesia, allodynia and nociception in diabetic mice using a mechanism involving the sigma receptor system.

Molecular pain, 2011, Oct-31, Volume: 7

Topics: Animals; Blotting, Western; Diabetes Mellitus, Experimental; Dipeptides; Hyperalgesia; Male; MAP Kinase Signaling System; Mice; Mice, Inbred ICR; Nociception; Pentazocine; Phosphorylation; Receptors, sigma; Reverse Transcriptase Polymerase Chain Reaction

2011